WO2023037337 - PHARMACEUTICAL COMPOSITIONS FOR IMAGING, DIAGNOSIS AND TREATMENT OF CANCER
National phase entry:
Publication Number
WO/2023/037337
Publication Date
16.03.2023
International Application No.
PCT/IB2022/058583
International Filing Date
12.09.2022
Title **
[English]
PHARMACEUTICAL COMPOSITIONS FOR IMAGING, DIAGNOSIS AND TREATMENT OF CANCER
[French]
COMPOSITIONS PHARMACEUTIQUES POUR L'IMAGERIE, LE DIAGNOSTIC ET LE TRAITEMENT DU CANCER
Applicants **
JUBILANT DRAXIMAGE INC.
16751 TransCanada Highway, Kirkland,
Montreal, Québec H9H 414, CA
Inventors
KULANGARA, Vijayaraj Kuniyil
16751 TransCanada Highway, Kirkland,
Montreal, Québec H9H 4J4, CA
NANDI, Indranil
790 Township Line Road, Suite 325,
Yardley, Pennsylvania 19067, US
PENA, Miriam Ruiz
16751 TransCanada Highway, Kirkland,
Montreal, Québec H9H 4J4, CA
MUKHERJEE, Tusharmouli
16751 TransCanada Highway, Kirkland,
Montreal, Québec H9H 4J4, CA
ZRIBA, Riadh
16751 TransCanada Highway, Kirkland,
Montreal, Québec H9H 4J4, CA
Priority Data
63/243,588
13.09.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CIPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1217 | |
| EPO | Filing, Examination | 7685 | |
| Japan | Filing | 592 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 3910 |
Total: 13978 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to a pharmaceutical cold kit composition comprising a chelating agent linked to somatostatin receptor binding organic moiety, a stabilizer, a buffer, and a caking agent or bulking agent, wherein the composition is free of sequestering agent. Further, the present invention also relates to the process of preparing reconstituted or radiolabeled solution composition having high in use stability and radiochemical purity and use thereof for diagnostic and/or therapeutic purposes.[French]
La présente invention concerne une composition pharmaceutique de "kit froid" comprenant un agent chélatant lié à une fraction organique de liaison au récepteur de la somatostatine, un stabilisant, un tampon et un agent agglomérant ou un agent gonflant, la composition étant exempte d'agent séquestrant. En outre, la présente invention concerne également le procédé de préparation de la composition de solution reconstituée ou radiomarquée ayant une stabilité d'utilisation et une pureté radiochimique élevées et son utilisation à des fins diagnostiques et/ou thérapeutiques.